![Kidney cancer biomarkers and targets for therapeutics: survivin (BIRC5), XIAP, MCL-1, HIF1α, HIF2α, NRF2, MDM2, MDM4, p53, KRAS and AKT in renal cell carcinoma | Journal of Experimental & Clinical Cancer Research Kidney cancer biomarkers and targets for therapeutics: survivin (BIRC5), XIAP, MCL-1, HIF1α, HIF2α, NRF2, MDM2, MDM4, p53, KRAS and AKT in renal cell carcinoma | Journal of Experimental & Clinical Cancer Research](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs13046-021-02026-1/MediaObjects/13046_2021_2026_Fig5_HTML.png)
Kidney cancer biomarkers and targets for therapeutics: survivin (BIRC5), XIAP, MCL-1, HIF1α, HIF2α, NRF2, MDM2, MDM4, p53, KRAS and AKT in renal cell carcinoma | Journal of Experimental & Clinical Cancer Research
![Frontiers | IFI16 Can Be Used as a Biomarker for Diagnosis of Renal Cell Carcinoma and Prediction of Patient Survival Frontiers | IFI16 Can Be Used as a Biomarker for Diagnosis of Renal Cell Carcinoma and Prediction of Patient Survival](https://www.frontiersin.org/files/MyHome%20Article%20Library/599952/599952_Thumb_400.jpg)
Frontiers | IFI16 Can Be Used as a Biomarker for Diagnosis of Renal Cell Carcinoma and Prediction of Patient Survival
![Kidney cancer biomarkers and targets for therapeutics: survivin (BIRC5), XIAP, MCL-1, HIF1α, HIF2α, NRF2, MDM2, MDM4, p53, KRAS and AKT in renal cell carcinoma | Journal of Experimental & Clinical Cancer Research Kidney cancer biomarkers and targets for therapeutics: survivin (BIRC5), XIAP, MCL-1, HIF1α, HIF2α, NRF2, MDM2, MDM4, p53, KRAS and AKT in renal cell carcinoma | Journal of Experimental & Clinical Cancer Research](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs13046-021-02026-1/MediaObjects/13046_2021_2026_Fig22_HTML.png)
Kidney cancer biomarkers and targets for therapeutics: survivin (BIRC5), XIAP, MCL-1, HIF1α, HIF2α, NRF2, MDM2, MDM4, p53, KRAS and AKT in renal cell carcinoma | Journal of Experimental & Clinical Cancer Research
![Kidney cancer biomarkers and targets for therapeutics: survivin (BIRC5), XIAP, MCL-1, HIF1α, HIF2α, NRF2, MDM2, MDM4, p53, KRAS and AKT in renal cell carcinoma | Journal of Experimental & Clinical Cancer Research Kidney cancer biomarkers and targets for therapeutics: survivin (BIRC5), XIAP, MCL-1, HIF1α, HIF2α, NRF2, MDM2, MDM4, p53, KRAS and AKT in renal cell carcinoma | Journal of Experimental & Clinical Cancer Research](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs13046-021-02026-1/MediaObjects/13046_2021_2026_Fig1_HTML.png)
Kidney cancer biomarkers and targets for therapeutics: survivin (BIRC5), XIAP, MCL-1, HIF1α, HIF2α, NRF2, MDM2, MDM4, p53, KRAS and AKT in renal cell carcinoma | Journal of Experimental & Clinical Cancer Research
![Diseases | Free Full-Text | Proficient Novel Biomarkers Guide Early Detection of Acute Kidney Injury: A Review Diseases | Free Full-Text | Proficient Novel Biomarkers Guide Early Detection of Acute Kidney Injury: A Review](https://www.mdpi.com/diseases/diseases-11-00008/article_deploy/html/images/diseases-11-00008-g001.png)
Diseases | Free Full-Text | Proficient Novel Biomarkers Guide Early Detection of Acute Kidney Injury: A Review
![Molecular Subsets in Renal Cancer Determine Outcome to Checkpoint and Angiogenesis Blockade - ScienceDirect Molecular Subsets in Renal Cancer Determine Outcome to Checkpoint and Angiogenesis Blockade - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S1535610820305420-fx1.jpg)
Molecular Subsets in Renal Cancer Determine Outcome to Checkpoint and Angiogenesis Blockade - ScienceDirect
![Cancers | Free Full-Text | From Immunohistochemistry to New Digital Ecosystems: A State-of-the-Art Biomarker Review for Precision Breast Cancer Medicine Cancers | Free Full-Text | From Immunohistochemistry to New Digital Ecosystems: A State-of-the-Art Biomarker Review for Precision Breast Cancer Medicine](https://www.mdpi.com/cancers/cancers-14-03469/article_deploy/html/images/cancers-14-03469-g001.png)
Cancers | Free Full-Text | From Immunohistochemistry to New Digital Ecosystems: A State-of-the-Art Biomarker Review for Precision Breast Cancer Medicine
![Tumor and immune reprogramming during immunotherapy in advanced renal cell carcinoma - ScienceDirect Tumor and immune reprogramming during immunotherapy in advanced renal cell carcinoma - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S1535610821001173-fx1.jpg)
Tumor and immune reprogramming during immunotherapy in advanced renal cell carcinoma - ScienceDirect
![Mapping the immune environment in clear cell renal carcinoma by single-cell genomics | Communications Biology Mapping the immune environment in clear cell renal carcinoma by single-cell genomics | Communications Biology](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs42003-020-01625-6/MediaObjects/42003_2020_1625_Fig1_HTML.png)
Mapping the immune environment in clear cell renal carcinoma by single-cell genomics | Communications Biology
![Novel Liquid Biomarkers and Innovative Imaging for Kidney Cancer Diagnosis: What Can Be Implemented in Our Practice Today? A Systematic Review of the Literature - ScienceDirect Novel Liquid Biomarkers and Innovative Imaging for Kidney Cancer Diagnosis: What Can Be Implemented in Our Practice Today? A Systematic Review of the Literature - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S2588931120302194-gr1.jpg)
Novel Liquid Biomarkers and Innovative Imaging for Kidney Cancer Diagnosis: What Can Be Implemented in Our Practice Today? A Systematic Review of the Literature - ScienceDirect
![Kidney cancer biomarkers and targets for therapeutics: survivin (BIRC5), XIAP, MCL-1, HIF1α, HIF2α, NRF2, MDM2, MDM4, p53, KRAS and AKT in renal cell carcinoma | Journal of Experimental & Clinical Cancer Research Kidney cancer biomarkers and targets for therapeutics: survivin (BIRC5), XIAP, MCL-1, HIF1α, HIF2α, NRF2, MDM2, MDM4, p53, KRAS and AKT in renal cell carcinoma | Journal of Experimental & Clinical Cancer Research](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs13046-021-02026-1/MediaObjects/13046_2021_2026_Fig3_HTML.png)